Regeneron has terminated its TITAN Phase I/IIa trial of REGN7041, an anti-CD3 monoclonal antibody in noninfectious uveitis, after a safety event triggered an unfavorable risk-versus-benefit assessment. The study had enrolled only one adult patient before stopping. Regeneron said the investigation into the event has not identified the underlying cause, and that patient safety remains its top priority as it evaluates available data. The outcome adds to a period of antibody program volatility, including recent failures reported across oncology and inflammatory disease. For the field, the trial termination highlights the importance of safety signal resolution early in development—particularly for immune-modulating CD3-directed approaches where systemic risk can complicate dosing strategy.